ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative.

ÌÇÐÄ´«Ã½

CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Annals of surgical oncology Roife, D. n., Powers, B. D., Zaidi, M. Y., Staley, C. A., Cloyd, J. M., Ahmed, A. n., Grotz, T. n., Leiting, J. n., Fournier, K. n., Lee, A. J., Veerapong, J. n., Baumgartner, J. M., Clarke, C. n., Patel, S. H., Hendrix, R. J., Lambert, L. n., Abbott, D. E., Pokrzywa, C. n., Lee, B. n., Blakely, A. n., Greer, J. n., Johnston, F. M., Laskowitz, D. n., Dessureault, S. n., Dineen, S. P. 2020

Abstract

CRS/HIPEC is thought to confer a survival advantage for patients with malignant peritoneal mesothelioma (MPM). However, the impact of nonperitoneal organ resection is not clearly defined. We evaluated the impact of major organ resection (MOR) on postoperative outcomes and overall survival (OS).The US HIPEC collaborative database (2000-2017) was reviewed for MPM patients who underwent CRS/HIPEC. MOR was defined as total or partial resection of diaphragm, stomach, spleen, pancreas, small bowel, colon, rectum, kidney, ureter, bladder, and/or uterus. MOR was categorized as 0, 1, or 2+?organs.A total of 174 patients were identified. Median PCI was 16 (3-39). The distribution of patients with MOR-0, MOR-1, and MOR-2+?was 94, 45, and 35 patients, respectively. MOR-1 and MOR-2+?groups had a higher frequency of any complication compared with MOR-0 (57.8%, 74.3%, and 48.9%, respectively, p?=?0.035), but Clavien 3/4 complications were similar. Median length of stay was slightly higher in the MOR-1 and MOR-2+?groups (10 and 11 days) compared with the MOR-0 cohort (9 days, p?=?0.005). Incomplete cytoreduction, ASA class 4, and male gender were associated with increased mortality on unadjusted analysis; however, their impact on OS was attenuated on multivariable analysis. MOR was not associated with OS based on these data (MOR-1: HR 1.67, 95% CI 0.59-4.74; MOR-2+?: HR 0.77, 95% CI 0.22-2.69).MOR was not associated with an increase in major complications or worse OS in patients undergoing CRS/HIPEC for MPM and should be considered, if necessary, to achieve complete cytoreduction for MPM patients.

View details for

View details for